Patents by Inventor Rudolf Markstein

Rudolf Markstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzo [g] quinoline derivatives for treating glaucoma and myopia
    Patent number: 7105528
    Abstract: The invention provides a compound of formula I wherein A, B, X, Y and R1 are as defined in the description, and a process for preparing them. The compounds of formula I are useful as pharmaceuticals.
    Type: Grant
    Filed: July 8, 2002
    Date of Patent: September 12, 2006
    Assignee: Novartis AG
    Inventors: Rudolf Markstein, Peter Gull, Esteban Pombo Villar
  • Ophthalmic use
    Publication number: 20060142249
    Abstract: The present invention relates to the use of a GABA-C-antagonist in the preparation of a medicament for the treatment of myopia.
    Type: Application
    Filed: June 27, 2003
    Publication date: June 29, 2006
    Inventors: Wolfgang Froestl, Rudolf Markstein, Katrina Schmid, Anne-Ulrike Trendelenburg
  • Benzo [g] quinoline derivatives for treating glaucoma and myopia
    Publication number: 20040171628
    Abstract: The invention provides a compound of formula I wherein A, B, X, Y and R1 are as defined in the description, and a process for preparing them. The compounds of formula I are useful as pharmaceutical agents for the treatment of glaucoma and myopia.
    Type: Application
    Filed: January 8, 2004
    Publication date: September 2, 2004
    Inventors: Rudolf Markstein, Peter Gull, Esteban Pombo Villar
  • Benzo[g]quinoline derivatives
    Patent number: 6057334
    Abstract: The invention provides a compound of formula (I) wherein A, B, X, Y and R are as defined in the description, and a process for preparing them. The compounds of formula (I) arc useful as pharmaceuticals for the treatment of glaucoma and myopia.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: May 2, 2000
    Assignee: Novartis AG
    Inventors: Peter Gull, Rudolf Markstein, Max Peter Seiler
  • Benzo?G!quinolines for use in prevention or delay of progressive atrophy of the optic nerve
    Patent number: 5955468
    Abstract: Compounds of formula I ##STR1## wherein A, B, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined in the description, are useful for the treatment of conditions where prevention or delay of progressive atrophy of the optic nerve is desirable.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 21, 1999
    Assignee: Sandoz Ltd.
    Inventor: Rudolf Markstein
  • Benzoquinoxalines, pharmaceutical compositions containing them and their use in treating schizophrenia
    Patent number: 5538971
    Abstract: 6-hydroxy or 6-alkoxy-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoxalines bearing in position 4 an optionally substituted phenyl group may be used in the treatment of schizophrenia, drug abuse or self-injurious behavior.
    Type: Grant
    Filed: May 27, 1994
    Date of Patent: July 23, 1996
    Assignee: Sandoz Ltd.
    Inventors: Peter Gull, Rudolf Markstein, Robert Swoboda
  • Octahydrobenzo[g]quinoline
    Patent number: 5262422
    Abstract: The invention relates to the compound of formula I ##STR1## in free base form or in acid addition salt form its preparation and use as a medicament for glaucoma, depression, Morbus Parkinsonism or cocaine abuse.
    Type: Grant
    Filed: February 19, 1993
    Date of Patent: November 16, 1993
    Assignee: Sandoz Ltd.
    Inventors: Peter Gull, Rudolf Markstein
  • Uses of dopamine receptor agonists
    Patent number: 4855306
    Abstract: Selective dopamine D1 receptor agonists for use in the treatment of primary degenerative dementia, depression, anxiety, obesity or schizophrenia.
    Type: Grant
    Filed: April 7, 1988
    Date of Patent: August 8, 1989
    Assignee: Sandoz Ltd.
    Inventors: Rudolf Markstein, Jose Palacios